Pathophysiology and management of diabetic retinopathy

Expert Review of Ophthalmology

Volumn 4, Issue 6, 2009, Pages 627-647

  Abu El Asrar, Ahmed M ^a   Al Mezaine, Hani S ^b   Ola, Mohammad Shamsul ^b  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Advanced glycation end product; Diabetic retinopathy; Inflammation; Neurodegeneration; Oxidative stress; PPAR ; Protein kinase C; Renin angiotensin system; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; AFLIBERCEPT; ALDOSE REDUCTASE INHIBITOR; ALDOSTERONE; AMINOGUANIDINE; ANGIOTENSIN; ANTIOXIDANT; BEVACIZUMAB; FENOFIBRATE; GROWTH HORMONE; HYALURONIDASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN; LISINOPRIL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEGAPTANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; PROTEIN KINASE C; RANIBIZUMAB; RENIN; ROSIGLITAZONE; RUBOXISTAURIN; SMALL INTERFERING RNA; SOMATOMEDIN; SOMATOSTATIN; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ANTISENSE THERAPY; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TARGETING; ENDOPHTHALMITIS; EVIDENCE BASED PRACTICE; EYE INFLAMMATION; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET TRANSPLANTATION; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VIRAL GENE THERAPY; VISUAL DISORDER; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 75949102998     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.09.52     Document Type: Review

References (231)

1. Fong DS, Aiello L, Gardner TW et al. American Diabetes Association. Diabetic retinopathy. Diabetes Care 26 (1), 226-229 (2003).
2. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J. Clin. Invest. 97(12), 2883-2890 (1996).
3. Hammes HP, Strödter D, Weiss A, Bretzel RG, Federlin K, Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 38(6), 656-660 (1995).
4. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest. 102(4), 783-791 (1998).
5. Abu-El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes K. Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest. Ophthalmol. Vis. Sci. 45(8), 2760-2766 (2004).
6. Abu El-Asrar AM, Dralands L, Missotten L, Geboes K. Expression of antiapoptotic and propapoptotic molecules in diabetic retinas. Eye 21(2), 238-245 (2007).
7. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J. Physiol. 586(Pt 18), 4401-4408 (2008).
8. Mizutani M, Gerhardinger C, Lorenzi M. Müller cell changes in human diabetic retinopathy. Diabetes 47(3), 445-449 (1998).
9. Krady JK, Basu A, Allen CM et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54(5), 1559-1565 (2005).
10. Decanini A, Karunadharma PR, Nordgaard CL, Feng X, Olsen TW, Ferrington DA. Human retinal pigment epithelium proteome changes in early diabetes. Diabetologia 51(6), 1051-1061 (2008).
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977-986 (1993).
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352(9131), 837-853 (1998).
13. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp. Mol. Pathol. 75(1), 95-108 (2003).
14. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 27(5 Pt 1), 535-542 (2001).
15. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318(20), 1315-1321 (1988).
16. Dolhofer-Bliesener R, Lechner B, Gerbitz KD. Possible significance of advanced glycation end products in serum in end-stage renal disease and in late complications of diabetes. Eur. J. Clin. Chem. Clin. Biochem. 34(4), 355-361 (1996).
17. Abu El-Asrar AM, Missotten L, Geboes K. Expression of advanced glycation end products and related molecules in diabetic fibrovascular epiretinal membranes. Clin. Exp. Ophthalmol. (2009) (In Press).
18. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114(6), 597-605 (2006).
19. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93(4), 1143-1152 (2008).
20. Wang Y, Vom Hagen F, Pfister F et al. Receptor for advanced glycation end product expression in experimental diabetic retinopathy. Ann. NY Acad. Sci. 1126, 42-45 (2008).
21. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47(6), 945-952 (1998).
22. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol. Cell Biol. Res. Commun. 3(6), 380-388 (2000).
23. Warboys CM, Toh HB, Fraser PA. Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest. Ophthalmol. Vis. Sci. 50(3), 1319-1328 (2009).
24. Yamagishi S, Yonekura H, Yamamoto Y et al. Advanced glycation end productsdriven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272(13), 8723-8730 (1997).
25. Okamoto T, Yamagishi S, Inagaki Y et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 16(14), 1928-1930 (2002).
26. Okamoto T, Tanaka S, Stan AC et al. Advanced glycation end products induce angiogenesis in vivo. Microvasc. Res. 63(2), 186-195 (2002).
27. Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-β. J. Lab. Clin. Med. 138(1), 59-68 (2001).
28. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 14(8 Suppl. 3), S254-S258 (2003).
29. Kita T, Hata Y, Kano K et al. Transforming growth factor-β2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes 56(1), 231-238 (2007).
30. Abu El-Asrar AM, Van den Steen PE, Al-Amro SA, Missotten L, Opdenakker G, Geboes K. Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int. Ophthalmol. 27(1), 11-22 (2007).
31. Tikellis C, Cooper ME, Twigg SM, Burns WC, Tolcos M. Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. Endocrinology 145(2), 860-866 (2004).
32. Hinton DR, Spee C, He S et al. Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care 27(3), 758-764 (2004).
33. Kuiper EJ, de Smet MD, van Meurs JC et al. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch. Ophthalmol. 124(10), 1457-1462 (2006).
34. Kuiper EJ, van Zijderveld R, Roestenberg P et al. Connective tissue growth factor is necessary for retinal capillary basal lamina thickening in diabetic mice. J. Histochem. Cytochem. 56(8), 785-792 (2008).
35. Joussen AM, Poulaki V, Le ML et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18(12), 1450-1452 (2004).
36. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin. Immunopathol. 30(2), 65-84 (2008).
37. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 95103 (2007).
38. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 20(12), 1366-1369 (2006).
39. Doganay S, Evereklioglu C, Er H et al. Comparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16(2), 163-170 (2002).
40. Joussen AM, Poulaki V, Mitsiades N et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression. FASEB J. 16(3), 438-440 (2002).
41. Makino N, Maeda T, Sugano M, Satoh S, Watanabe R, Abe N. High serum TNF-α level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J. Diabetes Complicat. 19(6), 347-355 (2005).
42. Ben-Mahmud BM, Mann GE, Datti A, Orlacchio A, Kohner EM, Chibber R. Tumor necrosis factor-α in diabetic plasma increases the activity of core 2 GlcNAc-T and adherence of human leukocytes to retinal endothelial cells: significance of core 2 GlcNAc-T in diabetic retinopathy. Diabetes 53(11), 2968-2976 (2004).
43. Gao X, Belmadani S, Picchi A et al. Tumor necrosis factor-a induces endothelial dysfunction in Lepr(db) mice. Circulation 115(2), 245-254 (2007).
44. Gao X, Zhang H, Schmidt AM, Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in Type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 295(2), H491-H498 (2008).
45. Sainson RC, Johnston DA, Chu HC et al. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 111(10), 4997-5007 (2008).
46. Clauss M, Sunderkötter C, Sveinbjörnsson B et al. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 97(5), 1321-1329 (2001).
47. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1β signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56(1), 224-230 (2007).
48. Abu El-Asrar AM, Maimone D, Morse PH, Gregory S, Reder AT. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 114(6), 731-736 (1992).
49. Abu El-Asrar AM, Van Damme J, Put W et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am. J. Ophthalmol. 123(5), 599-606 (1997).
50. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116(1), 73-79 (2009).
51. Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur. Cytokine Netw. 17(3), 155-165 (2006).
52. Maier R, Weger M, Haller-Schober EM et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol. Vis. 14, 637-643 (2008).
53. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr. Eye Res. 14(11), 1045-1053 (1995).
54. Wada T, Furuichi K, Sakai N et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J. Am. Soc. Nephrol. 15(4), 940-948 (2004).
55. -/- mice. Am. J. Pathol. 159(2), 457-463 (2001).
56. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105(4), 1405-1407 (2005).
57. Tager AM, Kradin RL, LaCamera P et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am. J. Respir. Cell Mol. Biol. 31(4), 395-404 (2004).
58. Keane MP, Belperio JA, Arenberg DA et al. IFN-γ-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J. Immunol. 163(10), 5686-5692 (1999).
59. Bulter JM, Guthrie SM, Koc M et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J. Clin. Invest. 115(1), 86-93 (2005).
60. Abu El-Asrar AM, Struyf S, Verbeke H, Van Damme J, Geboes K. Circulating bone marrow-derived enedothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes. Acta Ophthalmol. DOI: 10.1111/j.1755-3768.2009.01700.x (2009) (Epub ahead of print).
61. + cells to endothelial progenitor cells. Circulation 117(2), 206-215 (2008).
62. Reddy K, Zhou Z, Jia SF et al. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. Int. J. Cancer 123(4), 831-837 (2008).
63. De Falco E, Porcelli D, Torella AR et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 104(12), 3472-3482 (2004).
64. Petrovic MG, Korosec P, Kosnik M, Hawlina M. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 143(1), 175-176 (2007).
65. Kuwano T, Nakao S, Yamamoto H et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 18(2), 300-310 (2004).
66. Bagi Z, Erdei N, Papp Z et al. Up-regulation of vascular cyclooxygenase-2 in diabetes mellitus. Pharmacol. Rep. 58(Suppl.), 52-56 (2006).
67. Abu El-Asrar AM, Missotten L, Geboes K. Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes. Br. J. Ophthalmol. 92(11), 1534-1539 (2008).
68. Cook-Johnson RJ, Demasi M, Cleland LG et al. Endothelial cell COX-2 expression and activity in hypoxia. Biochim. Biophys. Acta 1761(12), 1443-1449 (2006).
69. Du Y, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287(4), R735-R741 (2004).
70. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur. J. Pharmacol. 498(1-3), 275-278 (2004).
71. 2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells. Vascul. Pharmacol. 44(6), 411-416 (2006).
72. Abu El-Asrar AM, Desmet S, Meersschaert A, Dralands L, Missotten L, Geboes K. Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am. J. Ophthalmol. 132(4), 551-556 (2001).
73. Abu El-Asrar AM, Meersschaert A, Dralands L, Missotten L, Geboes K. Inducible nitric oxide synthase and vascular endothelial growth factor are colocalized in the retinas of human subjects with diabetes. Eye 18(3), 306-313 (2004).
74. Leal EC, Manivannan A, Hosoya K et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 48(11), 5257-5265 (2007).
75. Zheng L, Du Y, Miller C et al. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 50(9), 1987-1996 (2007).
76. Chan PS, Kanwar M, Kowluru RA. Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J. Diabetes Complications DOI: 10.1016/j.jdiacomp.2008.10.002 (2009) (Epub ahead of print).
77. Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab. Invest. 85(5), 597-607 (2005).
78. Noda K, Ishida S, Inoue M et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 44(5), 2163-2170 (2003).
79. Jin M, Kashiwagi K, Izuka Y, Tanaka Y, Imai M, Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21(1), 28-33 (2001).
80. Abu El-Asrar AM, Dralands L, Veckeneer M et al. Gelatinase B in proliferative vitreoretinal disorders. Am. J. Ophthalmol. 125(6), 844-851 (1998).
81. Descamps FJ, Martens E, Kangave D et al. The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp. Eye Res. 83(2), 401-407 (2006).
82. Tawfik A, Sanders T, Kahook K, Akeel S, Elmarakby A, Al-Shabrawey M. Suppression of retinal peroxisome proliferator-activated receptor g in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase. Invest. Ophthalmol. Vis. Sci. 50(2), 878-884 (2009).
83. Muranaka K, Yanagi Y, Tamaki Y et al. Effects of peroxisome proliferator-activated receptor g and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model. Invest. Ophthalmol. Vis. Sci. 47(10), 4547-4552 (2006).
84. Aljada A, O'Connor L, Fu YY, Mousa SA. PPAR γ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 11(4), 361-367 (2008).
85. Nagai N, Izumi-Nagai K, Oike Y et al. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-κB pathway. Invest. Ophthalmol. Vis. Sci. 48(9), 4342-4350 (2007).
86. Chen P, Scicli GM, Guo M et al. Role of angiotensin II in retinal leukostasis in the diabetic rat. Exp. Eye Res. 83(5), 1041-1051 (2006).
87. Fukumoto M, Takai S, Ishizaki E et al. Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a Type 2 diabetic rat model. Curr. Eye Res. 33(10), 885-891 (2008).
88. Kurihara T, Ozawa Y, Nagai N et al. Angiotension II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 57(8), 2191-2198 (2008).
89. Zheng Z, Chen H, Ke G et al. Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway. Diabetes 58(4), 954-964 (2009).
90. Sugiyama T, Okuno T, Fukuhara M et al. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of Type 2 diabetes. Exp. Eye Res. 85(3), 406-412 (2007).
91. Yamagishi S, Matsui T, Nakamura K et al. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc. Res. 75(1), 130-134 (2008).
92. Yamagishi S, Matsui T, Nakamura K et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 40(1), 10-15 (2008).
93. Silva KC, Rosales MA, Biswas SK, Lopes de Faria JB, Lopes de Faria JM. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes 58(6), 1382-1390 (2009).
94. Du Y, Miller CM, Kern TS. Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic. Biol. Med. 35(11), 1491-1499 (2003).
95. Kanwar M, Chan PS, Kern TS, Kowluru RA. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest. Ophthalmol. Vis. Sci. 48(8), 3805-3811 (2007).
96. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001).
97. Obrosova IG, Stevens MJ, Lang HJ. Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology 62(3), 172-180 (2001).
98. Al-Shabrawey M, Rojaz M, Sanders T et al. Role of NADPH oxidase in retinal vascular inflammation. Invest. Ophthalmol. Vis. Sci. 49(7), 3239-3244 (2008).
99. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev. Endocr. Metab. Disord. 9(4), 315-327 (2008).
100. Kowluru RA, Kowluru V, Xiong Y, Ho YS. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radic. Biol. Med. 41(8), 1191-1196 (2006).
101. Gálvez MI. Ruboxistaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review. Curr. Diabetes Rev. 5(1), 14-17 (2009).
102. King GL. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes. Ann. Med. 28(5), 427-432 (1996).
103. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. 55(6), 498-510 (2007).
104. Mohamed Q, Wong TY. Emerging drugs for diabetic retinopathy. Expert Opin. Emerg. Drugs 13(4), 675-694 (2008).
105. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp. Diabetes Res. 2007, 61038 (2007).
106. Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr. Drug Targets 6(4), 475-486 (2005).
107. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 53(9), 2404-2411 (2004).
108. Ola MS, Berkich DA, Xu Y et al. Analysis of glucose metabolism in diabetic rat retinas. Am. J. Physiol. Endocrinol. Metab. 290(6), E1057-E1067 (2006).
109. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280(6), C1358-C1366 (2001).
110. Dawson DW, Volpert OV, Gillis P et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285(5425), 245-248 (1999).
111. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331(22), 1480-1487 (1994).
112. Adamis AP, Miller JW, Bernal MT et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118(4), 445-450 (1994).
113. Spranger J, Osterhoff M, Reimann M et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50(12), 2641-2645 (2001).
114. Hirota K, Semenza GL. Regulation of angiogenesis by hopoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59(1), 15-26 (2006).
115. Abu El-Asrar AM, Missotten L, Geboes K. Expression of hypoxia-inducible factor-1α and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br. J. Ophthalmol. 91(6), 822-826 (2007).
116. Takagi H, Koyama S, Seike H et al. Potential role of the angiopoietin/tie 2 system in ischemia-induced retinal neovascularization. Invest. J. Ophthalmol. Vis. Sci. 44(1), 393-402 (2003).
117. Zhu Y, Lee C, Shen F, Du R, Young WL, Yang GY. Angiopoietin-2 facilitates vascular endothelial growth factor-induced angiogenesis in the mature mouse brain. Stroke 36(7), 1533-1537 (2005).
118. Ohashi H, Takagi H, Koyama S et al. Alterations in expression of angiopoietins and the Tie-2 receptor in the retina of streptozotocin induced diabetic rats. Mol. Vision 10, 608-617 (2004).
119. Watanabe D, Suzuma K, Suzuma I et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 139(3), 476-481 (2005).
120. Watanabe D, Suzuma K, Matsui S et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 353(8), 782-792 (2005).
121. Katsura Y, Okano T, Matsuno K et al. Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care 28(9), 2252-2254 (2005).
122. Inomata Y, Hirata A, Takahashi E, Kawaji T, Fukushima M, Tanihara H. Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport 15(5), 877-879 (2004).
123. Kase S, Saito W, Ohgami K et al. Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br. J. Ophthalmol. 91(10), 1376-1378 (2007).
124. Zheng L, Szabó C, Kern TS. Poly (ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-κB. Diabetes 53(11), 2960-2967 (2004).
125. Xu P, Chiu J, Feng B, Chen S, Chakrabarti S. PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes. Diabetes Metab. Res. Rev. 24(5), 404-412 (2008).
126. Drel VR, Xu W, Zhang J et al. Poly(ADP-ribose) polymerase inhibition counteracts cataract formation and early retinal changes in streptozotocin-diabetic rats. Invest. Ophthalmol. Vis. Sci. 50(4), 1778-1790 (2009).
127. Antonetti DA, Barber AJ, Bronson SK et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55(9), 2401-2411 (2006).
128. Ambati J, Chalam KV, Chawla DK et al. Elevated γ-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol. 115(9), 1161-1166 (1997).
129. Kowluru RA, Engerman RL, Case GL, Kern TS. Retinal glutamate in diabetes and effect of antioxidants. Nuerochem. Int. 38(5), 385-390 (2001).
130. Schmidt KG, Bergert H, Funk RH. Neurodegenerative diseases of the retina and potential for protection and recovery. Curr. Neuropharmacol. 6(2), 164-178 (2008).
131. Catalani E, Cervia D, Martini D et al. Changes in neuronal response to ischemia in retinas with genetic alterations of GH receptor expression. Eur. J. Neurosci. 25(5), 1447-1459 (2007).
132. Santiago AR, Rosa SC, Santos PF, Cristóvão AJ, Barber AJ, Ambrósio AF. Elevated glucose changes the expression of ionotropic glutamate receptor subunits and impairs calcium homeostasis in retinal neural cells. Invest. Ophthalmol. Vis. Sci. 47(9), 4130-4137 (2006).
133. Akiyama SK. Integrins in cell adhesion and signaling. Hum. Cell. 9(3), 181-186 (1996).
134. Ning A, Cui J, Maberley D, Ma P, Matsubara J. Expression of integrins in human proliferative diabetic retinopathy membranes. Can. J. Ophthalmol. 34(6), 683-688 (2008).
135. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin α v β 3 for angiogenesis. Science 264(5158), 569-571 (1994).
136. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79(7), 1157-1164 (1994).
137. 3 inhibit retinal neovascularization in a murine model. Lab. Invest. 75(4), 563-573 (1996).
138. 5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 47(4), 1600-1605 (2006).
139. Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and GH in diabetic retinopathy. Curr. Med. Chem. 13(27), 3307-3317 (2006).
140. Haurigot V, Villacampa P, Ribera A et al. Increased intraocular insulin-like growth factor-1 (IGF-1) triggers blood-retinal barrier breakdown. J. Biol. Chem. 284(34), 22961-22969 (2009).
141. Miller EC, Capps BE, Sanghani RR, Clemmons DR, Maile LA. Regulation of IGF-1 signaling in retinal endothelial cells by hyperglycemia. Invest. Ophthalmol. Vis. Sci. 48(8), 3878-3887 (2007).
142. Boehm BO. Use of long-acting GH analogue treatment in diabetic retinopathy. Dev. Ophthalmol. 39, 111-121 (2007).
143. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with Type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch. Ophthalmol. 126(12), 1707-1715 (2008). •• Intensive therapy that maintains near-normal glycemic levels for an average of 6.5 years has a beneficial effect on long-term complications that extends at least 10 years beyond the actual period of such therapy. Therapy that maintains higher glycosulated hemoglobin (HbA1c) levels has adverse effects on complications that persist beyond the period of high HbA1c levels.
144. Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch. Ophthalmol. 116(7), 874-886 (1998).
145. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 317(7160), 703-713 (1998).
146. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 85(1), 82-106 (1978).
147. Brucker AJ, Qin H, Antoszyk AN et al.; Diabetic Retinopathy Clinical Research Network. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch. Ophthalmol. 127(2), 132-140 (2009). •• Clinically meaningful differences are unlikely in optical coherence tomography thickness or visual acuity following panretinal photocoagulation in one sitting compared with four sittings.
148. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch. Ophthalmol. 103(12), 1796-1806 (1985).
149. Ferris F. Early photocoagulation in patients with either Type I or Type II diabetes. Trans. Am. Ophthalmol. Soc. 94, 503-537 (1996).
150. Fong DS, Strauber SF, Aiello LP et al.; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch. Ophthalmol. 125(4), 469-480 (2007).
151. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Arch. Ophthalmol. 103(11), 1644-1652 (1985).
152. Warnock GL, Thompson DM, Meloche RM et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in Type 1 diabetes. Transplantation 86(12), 1762-1766 (2008). •• Islet transplantation yields improved HbA1c and less progression of retinopathy compared with intensive medical therapy during 3 years follow-up.
153. Thompson DM, Begg IS, Harris C et al. Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy. Transplantation 85(10), 1400-1405 (2008).
154. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370(9600), 1687-1697 (2007).
155. Aiello LP, Davis MD, Girach A et al.; PKC-DRS2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113(12), 2221-2230 (2006).
156. KC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol. 125(3), 318-324 (2007).
157. Davis MD, Sheetz MJ, Aiello LP et al.; PKC-DRS2 Study Group. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 50(1), 1-4 (2009). •• Ruboxistaurin treatment may ameliorate diabetic macular edema-associated visual decline.
158. Cunningham ET Jr, Adamis AP, Altaweel M et al. A Phase II randomized double masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112(10), 1747-1757 (2005).
159. Adamis AP, Altaweel M, Bressler NM et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113(1), 23-28 (2006).
160. Chun DW, Heier JS, Topping TM et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113(10), 1706-1712 (2006).
161. Nguyen QD, Tatlipinar S, Shah SM et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol. 142(6), 961-969 (2006).
162. Do DV, Nguyen QD, Shah SM et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular edema. Br. J. Ophthalmol. 93(2), 144-149 (2009).
163. Arevalo JF, Sanchez JG, Fromow-Guerra J et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch. Clin. Exp. Ophthalmol. 247(6), 735-743 (2009).
164. Scott IU, Edwards AR, Beck RW et al.; Diabetic Retinopathy Clinical Research Network. A Phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114(10), 1860-1867 (2007).
165. Kook D, Wolf A, Kreutzer T et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 28(8), 1053-1060 (2008).
166. Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 28(9), 1314-1318 (2008).
167. Fang X, Sakaguchi H, Gomi F et al. Efficacy and safety of one intravitreal injection of bavacizumab in diabetic macular oedema. Acta Ophthalmol. 86(7), 800-805 (2008).
168. Paccola L, Costa RA, Folgosa MS et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME Study). Br. J. Ophthalmol. 92(1), 76-80 (2008).
169. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am. J. Ophthalmol. 144(1), 124-126 (2007).
170. Arevalo JF, Wu L, Sanchez JG et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 23(1), 117-123 (2009).
171. Jiang Y, Liang X, Li X et al. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol. 87(7), 736-740 (2008).
172. Beutel J, Peters S, Lüke M et al. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol. DOI: 10.1111/j.1755-3768.2008. 01355.x. (2008) (Epub ahead of print).
173. Wakabayashi T, Oshima Y, Sakaguchi H et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115(9), 1571-1580 (2008).
174. Mason JO III, Yunker JJ, Vail R, McGwin G Jr. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 28(9), 1319-1324 (2008). • Single intravitreal injection of bevacizumab before standard panretinal photocoagulation (PRP) may be beneficial in preventing PRP-induced visual dysfunction and foveal thickening in eyes with severe proliferative diabetic retinopathy and good vision.
175. Tonello M, Costa RA, Almeida FP et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol. 86(4), 385-389 (2008). • Adjunctive use of intravitreal bevacizumab with PRP was associated with a greater reduction in the area of active leaking new vessels than PRP alone in patients with high-risk proliferative diabetic retinopathy.
176. Cho WB, Oh SB, Moon JW, Kim HC. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 29(4), 516-522 (2009). • Intravitreal bevacizumab before PRP can be an effective adjunctive treatment to PRP in the treatment of high-risk proliferative diabetic retinopathy.
177. 8 10% infusion could be an effective adjunct to vitrectomy in accelerating postoperative vitreous clear-up for eyes with active proliferative diabetic retinopathy.
178. Rizzo S, Genovesi-Ebert F, Di Bartolo E et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch. Clin. Exp. Ophthalmol. 246(6), 837-842 (2008). • Intravitreal bavacizumab administrered prior to vitrectomy reduced active neovascularization, thus facilitating pars plana vitrectomy.
179. da R Lucena D, Ribeiro JA, Costa RA et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br. J. Ophthalmol. 93(5), 688-691 (2009).
180. Arevalo JF, Maia M, Flynn HW Jr et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br. J. Ophthalmol. 92(2), 213-216 (2008). • Tractional retinal detachment may occur or progress shortly following administration of intravitreal bevacizumab in patients with severe proliferative diabetic retinopathy.
181. Georgopoulos M, Polak K, Prager F, Prünte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br. J. Ophthalmol. 93(4), 457-462 (2009).
182. Massin P, Audren F, Haouchine B et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111(2), 218-224 (2004).
183. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch. Ophthalmol. 124(5), 653-658 (2006).
184. Beer PM, Bakri SJ, Singh RJ et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110(4), 681-686 (2003).
185. Gillies MC, Sutter FK, Simpson JM et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113(9), 1533-1538 (2006).
186. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115(9), 1447-1449 (2008). •• Over a 2-year period, focal/grid photocoagulation is more effective and has fewer side effects than 1-mg or 4-mg doses of preservative-free intravitreal triamcinolone for patients with diabetic macular edema.
187. Beck RW, Edwards AR, Aiello LP et al.; Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol. 127(3), 245-251 (2009). •• Results of 3-year visual outcome are consistent with the 2-year results. Most eyes receiving 4 mg of intravitreal triamcinolone are likely to require cataract surgery.
188. Lam DS, Chan CK, Mohamed S et al. Intravitreal triamcinoone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 114(12), 2162-2167 (2007).
189. Maia OO Jr, Takahashi BS, Costa RA et al. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am. J. Ophthalmol. 147(2), 291-297 (2009). • Combination of laser photocoagulation with intravitreal triamcinolone was associated with improved best-corrected visual acuity and decreased central macular thickness and total macular volume when compared with laser photocoagulation alone for the treatment of proliferative diabetic retinopathy with clinically significant macular edema.
190. Shimura M, Nakazawa T, Yasuda K et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am. J. Ophthalmol. 145(5), 854-861 (2008).
191. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv. Opthalmol. 53(2), 139-149 (2008).
192. Stolba U, Binder S, Gruber D et al. Vitrectomy for persistent diffuse diabetic macular edema. Am. J. Ophthalmol. 140, 295-301 (2005).
193. Recchia FM, Ruby AJ, Carvalho Recchia CA. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. Am. J. Ophthalmol. 139(3), 447-454 (2005).
194. Kumagai K, Furukawa M, Ogino N et al. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 29(4), 464-472 (2009). • Pars plana vitrectomy with and without internal limiting membrane peeling appears to be beneficial to eyes with diffuse nontractinal diabetic macular edema, and its effectiveness is maintained in the long term.
195. Yamamoto T, Takeuchi S, Sato Y, Yamashita H. Long-term follow-up results of pars plana vitrectomy for diabetic macular edema. Jpn J. Ophthalmol. 51(4), 285-291 (2007).
196. Massin P, Duguid G, Erginay A et al. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am. J. Ophthalmol. 135(2), 169-177 (2003).
197. Thomas D, Bunce C, Moorman C, Laidlaw DA. A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br. J. Ophthalmol. 89(1), 81-86 (2005).
198. Shah SP, Patel M, Thomas D et al. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. Br. J. Ophthalmol. 90(1), 33-36 (2006).
199. Figueroa M, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina 28(3), 420-426 (2008). • In diffuse diabetic macular edema with no retinal traction, vitrectomy produces a short-term improvement in retinal thickness but no long-term anatomical or functional improvements.
200. Patel JI, Hykin PG, Schadt M et al. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina 26(1), 5-13 (2006).
201. Yamamoto T, Hitani K, Sato Y et al. Vitrecotmy for diabetic macular edema with and without internal limiting membrane removal. Ophthalmologica 219(4), 206-213 (2005).
202. Kuppermann BD, Thomas EL, de Smet MD et al.; Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol. 140(4), 573-584 (2005).
203. Chaturvedi N, Sjølie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351(9095), 28-31 (1998).
204. Chaturvedi N, Porta M, Klein R et al. Effect of Candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in Type 1 diabetes: randomised, placebo-controlled trials. Lancet 372(9647), 1394-1402 (2008).
205. Sjølie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in Type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372(9647), 1385-1393 (2008).
206. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch. Ophthalmol. 126(6), 793-799 (2008).
207. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am. J. Ophthalmol. 147(4), 583-586 (2009).
208. Ryan EH Jr, Han DP, Ramsay RC et al. Diabetic macular edema associated with glitazone use. Retina 26(5), 562-570 (2006).
209. Tatti P, Arrigoni F, Longobardi A, Costanza F, Di Blasi P, Merante D. Retrospective analysis of rosiglitazone and macular oedema in patients with Type 2 diabetes mellitus. Clin. Drug Investig. 28(5), 327-332 (2008).
210. Hammes HP, Strödter D, Weiss A, Bretzel RG, Federlin K, Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 38(6), 656-660 (1995).
211. Stitt A, Gardiner TA, Alderson NL et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51(9), 2826-2832 (2002).
212. Bhatwadekar A, Glenn JV, Figarola JL, et al. A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br. J. Ophthalmol. 92(4), 545-547 (2008).
213. Kaji Y, Usui T, Ishida S et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest. Ophthalmol. Vis. Sci. 48(2), 858-865 (2007).
214. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 55(10), 2757-2762 (2006).
215. Drel VR, Pacher P, Ali TK et al. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int. J. Mol. Med. 21(6), 667-676 (2008).
216. Obrosova IG, Minchenko AG, Vasupuram R et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52(3), 864-871 (2003).
217. Kern TS, Miller CM, Du Y et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 56(2), 373-379 (2007).
218. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47(3), 1149-1160 (2006).
219. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based antiinflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 56(2), 337-345 (2007).
220. Yang LP, Sun HL, Wu LM et al. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 50(5), 2319-2327 (2009).
221. Hattori Y, Hashizume K, Nakajima K, Nishumura Y, Naka M, Miyanaga K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Curr. Med. Res. Opin. 23(8), 1913-1917 (2007).
222. Kowluru RA, Kanwar M, Chan PS, Zhang JP. Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients. Arch. Ophthalmol. 126(9), 1266-1272 (2008).
223. Xia XB, Xiong SQ, Xu HZ, Jiang J, Li Y. Suppression of retinal neovascularization by shRNA targeting HIF-1α. Curr. Eye Res. 33(10), 892-902 (2008).
224. Jiang J, Xia XB, Xu HZ et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1α and VEGF. J. Cell Physiol. 218(1), 66-74 (2009).
225. Santulli RJ, Kinney WA, Ghosh S et al. Studies with an orally bioavailable α V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J. Pharmacol. Exp. Ther. 324(3), 894-901 (2008).
226. Kusari J, Zhou s, Padillo E, Clarke KG, Gil DW. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest. Opthalmol. Vis. Sci. 48(11), 5152-5159 (2007).
227. Smith SB, Duplantier J, Dun Y et al. In vivo protection against retinal neurodegeneration by σ receptor 1 ligand (+)- pentazocine. Invest. Ophthalmol. Vis. Sci. 49(9), 4154-4161 (2008).
228. Kalluri R, Kanasaki K. RNA interference: generic block on angiogenesis. Nature 452(7178), 543-545 (2008).
229. Wilkinson-Berka JL, Lofthouse S, Jaworski K, Ninkovic S, Tachas G, Wraight CJ. An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularizatin in a mouse model of retinopathy. Mol. Vis. 13, 1529-1538 (2007).
230. Rota R, Riccioni T, Zaccarini M et al. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J. Gene Med. 6(9), 992-1002 (2004).
231. Lamartina S, Cimino M, Roscilli G et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J. Gene Med. 9(10), 862-874 (2007).